Current clinical guidelines for the prevention of cardiovascular disease were not found to fully take into account to the polygenicity underlying coronary artery disease susceptibility.
The Food and Drug Administration has approved Brilinta (ticagrelor; AstraZeneca) to reduce the risk of a first myocardial infarction (MI) or stroke in high-risk patients with coronary artery disease (CAD).
High-risk plaque criteria evaluated on computed tomography angiography were found to provide added value for the prediction of long-term outcomes in patients with coronary artery disease.
Study finds no incremental benefit of an percutaneous coronary intervention or coronary artery bypass grafting in patients with stable coronary disease and advanced chronic kidney disease.
The reduction in left ventricular mass observed in patients with stable coronary artery disease and type 2 diabetes treated with empagliflozin may not result of an effect of this drug on diastolic function.
Genetic testing is not better at predicting coronary heart disease risk compared with conventional risk factors.
The treatment of proximal left anterior descending coronary artery lesions using new-generation drug-eluting stents was not found to be associated with higher rates of adverse clinical events at 2 years.
The majority of patients with acute coronary syndrome treated with statins were found to have low-density lipoproteins-cholesterol levels above those recommended by current guidelines.
For patients with stable coronary disease and moderate-to-severe ischemia, an initial invasive strategy does not improve outcomes, but it may improve angina-related health status.
18F-sodium fluoride coronary positron emission tomography may help predict the development of myocardial infarction in patients with advanced coronary artery disease.